ArticleJournal of neuro-oncology2006
Reduced glioma infiltration in Src-deficient mice.
Article in Journal of neuro-oncology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.Journal of neuro-oncology · 2015Trial
- EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.Neuro-oncology · 2012Trial
- Review
- A Linear Variant of Segmental Schwannomatosis Localized to the Upper Extremity.Journal of hand and microsurgery · 2022Article
- Article
- Role of KCa3.1 Channels in Modulating CaInternational journal of molecular sciences · 2018Review
- A Short Region of Connexin43 Reduces Human Glioma Stem Cell Migration, Invasion, and Survival through Src, PTEN, and FAK.Stem cell reports · 2017Article
- Src family kinases differentially influence glioma growth and motility.Molecular oncology · 2015Article
- Silencing of the tumor suppressor gene WNK2 is associated with upregulation of MMP2 and JNK in gliomas.Oncotarget · 2015Article
- The role of Src family kinases in growth and migration of glioma stem cells.International journal of oncology · 2014Article
- Identification of key signaling molecules involved in the activation of the swelling-activated chloride current in human glioblastoma cells.The Journal of membrane biology · 2014Article
- A graphic method for identification of novel glioma related genes.BioMed research international · 2014Article
- Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.Molecular cancer therapeutics · 2013Article
- SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition.PloS one · 2013Article
- Article
- Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.Journal of neuro-oncology · 2012Article
- Specific inhibition of SRC kinase impairs malignant glioma growth in vitro and in vivo.Molecular therapy. Nucleic acids · 2012Article
- Direct inhibition of myosin II effectively blocks glioma invasion in the presence of multiple motogens.Molecular biology of the cell · 2012Article
- Expression and Role of the Intermediate-Conductance Calcium-Activated Potassium Channel KCa3.1 in Glioblastoma.Journal of signal transduction · 2012Article
- Non-invasive quantification of brain tumor-induced astrogliosis.BMC neuroscience · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Malignant brain tumors, such as glioblastoma, are characterized by extensive angiogenesis and permeability of the blood-brain barrier (BBB). The infiltration of glioma cells away from the primary tumor mass is a pathological characteristic of glial tumors. The infiltrating tumor cells represent a significant factor in tumor recurrence following surgical debulking, radiation, and chemotherapy treatments. Vascular endothelial growth factor (VEGF)-mediated vascular permeability (VP) has been associated with the progression of glioma tumor growth and infiltration into surrounding normal brain parenchyma. While VEGF induces a robust VP response in control mice (src+/+ or src+/-), the VP response is blocked in src-/- mice that demonstrate a 'leakage-resistant phenotype' in the brain. We used the Src-deficient mouse model to determine the role of Src in the maintenance of the BBB following orthotopic implantation and growth of glioma cells in the brain. Although solid tumor growth was the same in control and src-/- mice, the infiltrating component of glioma growth was reduced in src-/- mice. Characterization of the expression and localization of the extracellular matrix (ECM) protein fibrinogen was evaluated to determine the effect of a Src-mediated VP defect in the host compartment. These studies indicate that the reduced VP of host brain blood vessels of src-/- mice mediates a reduction in glioma cell invasion in a mouse brain tumor xenograft model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.